Mastocytosis, classification, biological diagnosis and therapy;Mastocytoses: Classification, diagnostic biologique et traitement

Annales de Biologie Clinique

Volumn 62, Issue 6, 2004, Pages 657-669

  Arock, M ^a  

^a CNRS   (France)

Author keywords

c kit; Classification; Mastocytosis; Tryptase

Indexed keywords

BONE MARROW EXAMINATION; CLASSIFICATION; CYTOLOGY; HUMAN; MAST CELL; MASTOCYTOSIS; PATHOLOGY; REVIEW;

BONE MARROW EXAMINATION; HUMANS; MAST CELLS; MASTOCYTOSIS;

EID: 9644257335     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ehrlich P. Beiträge zur kenntnis der granulierten bindegewebs zellen und der eosinophilen leukocyten. Arch Mikr Anat 1877 ; 13 : 263-77.
2. Valent P. Cytokines involved in growth and differentiation of human basophils and mast cells. Exp Dermatol 1995 ; 4 : 255-9.
3. Costa JJ, Weller PF, Galli SJ. The cells of the allergic response : mast cells, basophils, and eosinophils. JAMA 1997 ; 278 : 1815-22.
4. Feger F, Varadaradjalou S, Gao Z, Abraham SN, Arock M. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol 2002 ; 23 : 151-8.
5. Brockow K, Metcalfe DD. Mastocytosis. Curr Opin Allergy Clin Immunol 2001 ; 1 : 449-54.
6. Rosbotham JL, Malik NM, Syrris P, et al. Lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999 ; 140 : 849-52.
7. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000 ; 14 : 659-87.
8. Heide R, Tank B, Oranje AP. Mastocytosis in childhood. Pediatr Dermatol 2002 ; 19 : 375-81.
9. Ispas L, Henriksen RA, Metzger WJ. The many faces of systemic mastocytosis. Ann Allergy Asthma Immunol 2001 ; 87 : 6-14 ; quiz 15, 67.
10. Irani A, Schwartz L. Neutral proteases as indicators of human mast cell heterogeneity. Monogr Allergy 1990 ; 27 : 146-62.
11. Galli SJ. New insights into "the riddle of the mast cells" : microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990 ; 62 : 5-33.
12. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997 ; 77 : 1033-79.
13. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis : correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002; 128 : 136-41.
14. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992 ; 148 : 772-7.
15. Rottem M, Okada T, Goff JP, Metcalfe DD. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. Blood 1994 ; 84 : 2489-96.
16. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999 ; 94 : 2333-42.
17. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999 ; 31 : 1037-51.
18. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990 ; 63 : 225-33.
19. Blechman JM, Lev S, Givol D, Yarden Y. Structure-function analyses of the kit receptor for the steel factor. Stem Cells (Dayt) 1993 ; 11 (Suppl. 2) : 12-21.
20. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000 ; 14 : 517-35.
21. Deberry C, Mou S, Linnekin D. Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J 1997 ; 327 : 73-80.
22. Galli SJ, Tsai M, Gordon JR, Geissler EN, Wershil BK. Analyzing mast cell development and function using mice carrying mutations at W/c-kit or S1/MGF (SCF) loci. Ann NY Acad Sci USA 1992; 664: 69-88.
23. Piao X, Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996 ; 87 : 3117-23.
24. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis : a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002 ; 127 : 110-4.
25. Sperr WR, Escribano L, Jordan J, et al. Morphologic properties of neoplastic mast cells : delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001 ; 25 : 529-36.
26. Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 2002 ; 127 : 127-32.
27. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults : immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998 ; 91 : 2731-6.
28. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000 ; 14 : 537-55.
29. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis : state of the art. Br J Haematol 2003 ; 122 : 695-717.
30. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha : results of a multicentre phase II trial on 20 patients. Br J Haematol 2002 ; 119 : 1090-7.
31. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts 2nd LJ. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995 ; 104 : 937-40.
32. Granerus G, Lonnqvist B, Wass U. Determination of the histamine metabolite tele-methylimidazoleacetic acid and of creatinine in urine by the same HPLC system. Inflamm Res 1999 ; 48 : 75-80.
33. Akin C, Schwartz LB, Kitoh T, et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis : relationships to disease severity and bone marrow pathology. Blood 2000 ; 96 : 1267-73.
34. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001 ; 98 : 2200-9.
35. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002 ; 43 : 2257-61.
36. Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000 ; 14 : 641-57.
37. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002 ; 127 : 140-2.
38. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIPILI-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003 ; 102 : 3093-6.
39. Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002 ; 127 : 115-7.
40. Horny H, Valent P. Diagnosis of mastocytosis : general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001 ; 25 : 543-51.
41. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998 ; 22 : 1132-40.
42. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis : evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001 ; 32 : 545-52.
43. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 2003 ; 27 : 1013-9.
44. Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Bone marrow angiogenesis in systemic mast cell disease. J Hematother Stem Cell Res 2002 ; 11 : 139-46.
45. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders : current treatment options and proposed response criteria. Leuk Res 2003 ; 27 : 635-41.
46. Valent P, Horny H, Escribano L, et al. Diagnostic criteria and classification of mastocytosis : a consensus proposal. Leuk Res 2001 ; 25 : 603-25.
47. Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001 ; 25 : 563-70.
48. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis : current concepts in diagnosis and treatment. Ann Hematol 2002 ; 81 : 677-90.
49. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis : a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol 2002 ; 127 : 137-9.
50. Boissan M, Feger F, Guillosson JJ, Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 2000 ; 67 : 135-48.
51. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004 ; 103 : 3222-5.
52. Metcalfe DD. Classification and diagnosis of mastocytosis : current status. J Invest Dermatol 1991 ; 96 : 2S-4S.
53. Gasior-Chrzan B, Falk E. Systemic mastocytosis treated with histamine H1 and H2 receptors antagonists. Dermatology 1992 ; 184 : 149-52.
54. Mallet A, Norris P, Rendell N, Wong E, Greaves M. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. Br J Clin Pharmacol 1989 ; 27 : 88-91.
55. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004 ; 350 : 735-6.
56. Turk J, Oates J, Roberts LJ. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983 ; 71 : 189-92.
57. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis : report of five cases and review of the literature. Leuk Res 2004 ; 28 : 249-57.
58. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003 ; 102 : 4270-6.
59. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003 ; 362 : 535-6.
60. Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol 2004 ; 79 : 441-7.